Meeting
2021 ASCO Annual Meeting
Bone modifying agents in veterans with castration-resistant prostate cancer.
Authors
Jordan Bauman
University of Michigan, Ann Arbor, MI
Jordan Bauman , Kyle Kumbier , Jennifer A. Burns , Jordan Sparks , Phoebe A. Tsao , Ted A. Skolarus , Vahakn B. Shahinian , Megan Veresh Caram
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6582)
DOI
10.1200/JCO.2021.39.15_suppl.6582
Abstract #
6582
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Incidence of skeletal-related events in men with castration-resistant prostate cancer.
First Author: Alison Tse Kawai
Poster
2018 ASCO Annual Meeting
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.
First Author: Li Zhang
Poster
2016 Genitourinary Cancers Symposium
Serum parathyroid hormone and calcium changes in metastatic castration resistant prostate cancer patients receiving enzalutamide in post-docetaxel setting.
First Author: Angela Gernone
Poster
2023 ASCO Annual Meeting
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.
First Author: Alicia K. Morgans